Another important finding is that serum sCD14 was shown to be probably valuable for predicting the recurrence of breast cancer with LN-ER/PR+Her2- status after the analysis of those 12 relapsed patients in 3 years in enrolled 93LN-ER/PR+Her2- breast cancer patients. This evidence concerns the gene ESR1 and breast carcinoma.